CA3024910A1 - Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis - Google Patents
Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis Download PDFInfo
- Publication number
- CA3024910A1 CA3024910A1 CA3024910A CA3024910A CA3024910A1 CA 3024910 A1 CA3024910 A1 CA 3024910A1 CA 3024910 A CA3024910 A CA 3024910A CA 3024910 A CA3024910 A CA 3024910A CA 3024910 A1 CA3024910 A1 CA 3024910A1
- Authority
- CA
- Canada
- Prior art keywords
- pad4
- patient
- sample
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rehabilitation Therapy (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340560P | 2016-05-24 | 2016-05-24 | |
| US62/340,560 | 2016-05-24 | ||
| PCT/EP2017/062479 WO2017202879A1 (en) | 2016-05-24 | 2017-05-23 | Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3024910A1 true CA3024910A1 (en) | 2017-11-30 |
Family
ID=59009670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3024910A Pending CA3024910A1 (en) | 2016-05-24 | 2017-05-23 | Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11613580B2 (https=) |
| EP (1) | EP3464358A1 (https=) |
| JP (2) | JP7217631B2 (https=) |
| AU (1) | AU2017270027B2 (https=) |
| CA (1) | CA3024910A1 (https=) |
| MA (1) | MA45112A (https=) |
| WO (1) | WO2017202879A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017270027B2 (en) * | 2016-05-24 | 2024-07-11 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
| CA3129624A1 (en) * | 2019-02-15 | 2020-08-20 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing and assessing rheumatoid arthritis |
| US20210284744A1 (en) | 2020-03-15 | 2021-09-16 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
| CN111458522B (zh) * | 2020-04-20 | 2024-01-09 | 杭州英邈生物科技有限公司 | 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用 |
| CN111733151B (zh) * | 2020-07-13 | 2021-11-12 | 山东新创生物科技有限公司 | 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| CA2525179A1 (en) | 2003-05-08 | 2004-12-23 | Vanderbilt University | A gene equation to diagnose rheumatoid arthritis |
| PL1999152T3 (pl) | 2006-03-27 | 2013-05-31 | Medimmune Ltd | Element wiążący receptor GM-CSF |
| JP5252339B2 (ja) | 2007-12-25 | 2013-07-31 | 地方独立行政法人東京都健康長寿医療センター | Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法 |
| AU2010233926B2 (en) * | 2009-03-30 | 2014-01-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Biomarkers, methods and kits for the diagnosis of Rheumatoid Arthritis |
| WO2011066372A2 (en) | 2009-11-25 | 2011-06-03 | The Johns Hopkins University | Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity |
| EP2766394B1 (en) | 2011-10-10 | 2017-11-22 | Medimmune Limited | Treatment for rheumatoid arthritis |
| US8975033B2 (en) | 2012-11-05 | 2015-03-10 | The Johns Hopkins University | Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases |
| EP3145541A1 (en) | 2014-05-19 | 2017-03-29 | Medimmune Limited | Treatment for rheumatoid arthritis |
| AU2017270027B2 (en) * | 2016-05-24 | 2024-07-11 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
-
2017
- 2017-05-23 AU AU2017270027A patent/AU2017270027B2/en active Active
- 2017-05-23 WO PCT/EP2017/062479 patent/WO2017202879A1/en not_active Ceased
- 2017-05-23 EP EP17727829.8A patent/EP3464358A1/en active Pending
- 2017-05-23 MA MA045112A patent/MA45112A/fr unknown
- 2017-05-23 CA CA3024910A patent/CA3024910A1/en active Pending
- 2017-05-23 JP JP2018562123A patent/JP7217631B2/ja active Active
- 2017-05-23 US US16/304,055 patent/US11613580B2/en active Active
-
2023
- 2023-01-24 JP JP2023008716A patent/JP2023058524A/ja not_active Ceased
- 2023-02-14 US US18/169,205 patent/US20230303707A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023058524A (ja) | 2023-04-25 |
| US20230303707A1 (en) | 2023-09-28 |
| US20200317793A1 (en) | 2020-10-08 |
| AU2017270027B2 (en) | 2024-07-11 |
| MA45112A (fr) | 2019-04-10 |
| EP3464358A1 (en) | 2019-04-10 |
| JP2019523759A (ja) | 2019-08-29 |
| US11613580B2 (en) | 2023-03-28 |
| WO2017202879A1 (en) | 2017-11-30 |
| AU2017270027A1 (en) | 2018-12-06 |
| JP7217631B2 (ja) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230303707A1 (en) | Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis | |
| US11016099B2 (en) | Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers | |
| Salaffi et al. | Rheumatoid arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures | |
| US20220144935A1 (en) | Ccl20 as a predictor of clinical response to il23-antagonists | |
| WO2011014349A1 (en) | Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis | |
| WO2015034926A1 (en) | Treatment methods for rheumatoid arthritis | |
| AU2016349113A1 (en) | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases | |
| JP2013174442A (ja) | リウマチ障害と非リウマチ障害とを識別するためのトリガーアッセイ | |
| Koivula et al. | Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis | |
| Klawiter et al. | Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis | |
| JP6687391B2 (ja) | リウマチ性関節炎（ｒａ）の存在を決定するためのサンプルの測定方法 | |
| Hafez et al. | Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor | |
| Mian | The impact of moderate disease activity rheumatoid arthritis and evaluating the management of this cohort | |
| US20220373539A1 (en) | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers | |
| Akpınar et al. | A Cross-Sectional Study on Elevated Serum Calcitonin Gene-Related Peptide Levels in Rheumatoid Arthritis Patients and Their Relationship with Disease Activity | |
| Tikhonova et al. | Background and definition of the decision problem (s) | |
| Lamacchia et al. | Archive ouverte UNIGE | |
| Hassan et al. | Novel molecular diagnostic marker in the evaluation of cartilage destruction in patients with rheumatoid arthritis | |
| Kraev | Department of Propaedeutics of Internal Medicine Rheumatology Clinic Kaspela University Hospital, Plovdiv | |
| Taneja et al. | Fatigue in Rheumatoid Arthritis as Measured by BRAF-MDQ Score and its Relation to Serum Interleukin-6 Level | |
| Nam | Diagnosis and management of early inflammatory arthritis | |
| Oladapo | Medication adherence, persistence, switching and dose escalation with the use of tumor necrosis factor (TNF) inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis | |
| Ma et al. | AB0261 Matrix Metalloproteinase-3 as A Biomarker of Histological Synovitis in Rheumatoid Arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220518 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240806 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20241206 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |